Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-263 in Relapsed/Refractory B-Cell CLL
NCT00918450Phase 2Withdrawn
- Sponsor
- Abbott Laboratories
- Start
- Mar 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of navitoclax in chronic lymphocytic leukemia (CLL), sponsored by Abbott Laboratories. Planned start Mar 2010; status: withdrawn.
02
Drugs
navitoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00918450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00918450.